Pages
- About Us
- ACE
- Careers
- Contact Us
- COVID-19 Solutions
- Drug Product
Development & Manufacturing - Drug Substance
Development & Manufacturing - General Terms and Conditions
- Home
- How to comply with FDA and EMA regulations
- Legal entities Ardena
- Nanomedicine
- News & Insights
- Nitrosamines
- Privacy Policy
- Registration form
- Sitemap
- Upcoming events
- Webinar Archives
- Clinical Logistics
- Bioanalysis
- Dossier Development
Posts by category
- Category: Events
- Category: Insights
- Launch new Ardena career page
- Patrick Walleser, new Ardena Account Management Director DACH region
- EMA and FDA have activated plans to fast track the development and approval of therapeutics against COVID-19.
- EMA extends nitrosamine risk assessments to investigational drugs
- EMA request for Nitrosamine Risk Assessment
- Category: News
- Ardena acquires Idifarma from Suanfarma, adding spray drying technology and high potency capabilities
- Ardena’s expertise on drug substance development helps new treatment for Parkinson’s disease to the next phase
- Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands
- Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies
- Commercial Agency Agreement between Ardena and South Korean company Keyfronbio Co., Ltd.
- Investment in Flow Cytometry unlocks the secrets of single cells
- New cancer immunotherapy treatment enters clinical phase
- Commercial Agency Agreement Taiwan (ROC)
- CVC Credit Partners refinances Ardena’s credit facilities
- Ardena Assen is doubling its capacity – Update 25.03.2020
- GHO Capital acquires Ardena
- Ardena Assen is doubling its capacity
- BVA award nominee
- Ardena launches Life Science Ingredients Arm
- Ardena launches bimonthly newsletter
- Ardena cements growth and expansion with new headquarters
- Ardena expands nanomedicine capabilities
- Ardena acquires Syntagon and strengthens API offering
- Ardena acquires ChemConnection adding API expertise
- Ardena is expanding its Belgian site
- ABL acquisition extends early-phase offering
- Ardena launches following Pharmavize and Crystallics merger
- Category: Press Release
- Category: Newsletter
- Much more than just smoke – from marijuana to medicinal cannabis derived therapeutics
- Leverage the power of CMC in early drug development
- Prevent undesired immunogenicity from becoming the barrier for innovative biotherapeutics
- Discriminatory dissolution test method in late development
- Scientific Advice and Dialogue with EMA during Drug Development
- Oligonucleotide therapeutics: How to measure plasma concentration, tissue distribution and immunogenicity?
- Powder blending in early-phase drug product development: Balancing art and science
- How to obtain enantiopure drug substance through crystallization?
- How to enhance the safety of your drug substance synthesis process by smart chemical design?
- Ardena launches integrated drug discovery support services
- How to save significantly on early-phase clinical supply logistics?
- Which solubility-enhancing technology should I use to support my early drug development project?
- What is an acceptable impurity level for a drug substance used in GLP toxicology studies?
- When to conduct a polymorph screening?
Careers
- Technician LC-MSMS
- Drug product formulation scientist
- Project Manager (CMC)
- Global Regulatory CMC Manager
- Analytical Scientist of Nanomaterials
- Analytical Scientist NMR
- Technician, Analytical Sciences
- Validation Engineer
- Analist Immunochemie
- Analist Chromatografie
- Associate Scientist - Production
- Regulatory CMC Writer
- CMC Writer
- Scientist in Analytical Sciences of nanomaterials (PhD level)
- Analytical Scientist
- Drug Product Formulation Scientist
- Technician LC-MS/MS
- BSc/MSc in Analytical Chemistry